[1]SANTUCCI C,CARIOLI G,BERTUCCIO P,et al.Progress in cancer mortality,incidence,and survival:a global overview［J］.European Journal of Cancer Prevention,2020,29(5):367-381.
[2]ZENG H,CHEN W,ZHENG R,et al.Changing cancer survival in China during 2003-15:a pooled analysis of 17 population-based cancer registries［J］.Lancet Glob Health,2018,6(5):e555-e567.
[3]RELLI V,TREROTOLA M,GUERRA E,et al.Abandoning the notion of non-small cell lung cancer ［J］.Trends in Molecular Medicine,2019,25(7):585-594.
[4]YIN Y,XIE J,PENG F,et al.The topoisomerase inhibitor CPT-11 prevents the growth and metastasis of lung cancer cells in nude mice by inhibiting EGFR/MAPK signaling pathway［J］.Heliyon,2023,9(5):e15805.
[5]ATHAYA T,RIPAN RC,LI X,et al.Multimodal deep learning approaches for single-cell multi-omics data integration［J］.Briefings in Bioinformatics,2023,24(5):bbad313.
[6]张晓智,杨蕴一,孙宇晨,等.精准放疗的现状与进展［J］.西安交通大学学报(医学版),2020,41(05):633-638.
ZHANG XZ,YANG YY,SUN YC,et al.Current status and progress of precision radiotherapy［J］.Journal of Xi'an Jiaotong University(Medical Edition),2020,41(05):633-638.
[7]ZHANG H,HE M,WAN R,et al.Establishment and evaluation of EGFR mutation prediction model based on tumor markers and CT features in NSCLC［J］.Journal of Healthcare Engineering,2022,2022:8089750.
[8]SHI Y,WANG H,YAO X,et al.Machine learning prediction models for different stages of non-small cell lung cancer based on tongue and tumor marker:a pilot study［J］.BMC Medical Informatics and Decision Making,2023,23(1):197.
[9]LIU TC,JIN X,WANG Y,et al.Role of epidermal growth factor receptor in lung cancer and targeted therapies［J］.American Journal of Cancer Research,2017,7(2):187-202.
[10]KIM MJ,HA SJ,SO BR,et al.NADPH oxidase and epidermal growth factor receptor are promising targets of phytochemicals for ultraviolet-induced skin carcinogenesis［J］.Antioxidants(Basel,Switzerland),2021,10(12):1909.
[11]SWIATNICKI MR,RENNHACK JP,ORTIZ MMO,et al.Elevated phosphorylation of EGFR in NSCLC due to mutations in PTPRH［J］.PLoS Genetics,2022,18(9):e1010362.
[12]CHAN BA,HUGHES BG.Targeted therapy for non-small cell lung cancer:current standards and the promise of the future［J］.Translational Lung Cancer Research,2015,4(1):36-54.
[13]LIN YW,SU HC,RAJ EN,et al.Targeting EGFR and monitoring tumorigenesis of human lung cancer cells in vitro and in vivo using nanodiamond-conjugated specific EGFR antibody［J］.Pharmaceutics,2022,15(1):111.
[14]XU QD,HUANG S,YANG K.Combination immunochemotherapy for recurrent or metastatic head and neck squamous cell carcinoma:a systematic review and meta-analysis［J］.BMJ Open,2023,13(6):e069047.
[15]何婧怡,吴芳,胡春宏.第三代EGFR-TKIs治疗晚期非小细胞肺癌的耐药机制及应对策略研究进展［J］.肿瘤防治研究,2019,46(10):938-945.
WU JY,WU F,HU CH.Research progress of drug resistance mechanism and coping strategies of third-generation EGFR-TKIs in treatment of advanced non-small cell lung cancer ［J］.Cancer Prevention and Treatment Research,2019,46(10):938-945.
[16]高映浩，侯恩存，甘川.非小细胞肺癌EGFR-TKI获得性耐药后治疗策略的研究进展［J］.现代肿瘤医学,2018,26（14）:2285-2289.
GAO YJ,HOU EC,GAN C.The review of therapeutic approaches for NSCLC patients acquired drug-resistance after EGFR-TKI treatment［J］.Modern Oncology,2018,26（14）:2285-2289.
[17]AUSAWASAMRIT A,ITTHIWARAPORNKUL N,CHAOTHAM C,et al.Lupalbigenin from derris scandens sensitizes detachment-induced cell death in human lung cancer cells［J］.Anticancer Research,2015,35(5):2827-2834.
[18]SHAO X,CHEN X,WANG Z,et al.Diprenylated flavonoids from licorice induce death of SW480 colorectal cancer cells by promoting autophagy:Activities of lupalbigenin and 6,8-diprenylgenistein［J］.Journal of Ethnopharmacology,2022,296:115488.
[19]杨星莹,朱威巍,江丽,等.Lupalbigenin抑制Ba/F3 EGFR WT野生型肺癌细胞增殖作用机制［J］.热带农业科学,2022,42(08):44-50.
YANG XY,ZHU WW,JIANG L,et al.Inhibition of proliferation of Ba/F3 EGFR WT wild-type lung cancer cells by Lupalbigenin［J］.Tropical Agricultural Sciences,2022,42(08):44-50.
[20]HARRISON PT,VYSE S,HUANG PH.Rare epidermal growth factor receptor(EGFR) mutations in non-small cell lung cancer［J］.Seminars in Cancer Biology,2020,61:167-179.
[21]MARROCCO I,YARDEN Y.Resistance of lung cancer to EGFR-specific kinase inhibitors:Activation of bypass pathways and endogenous mutators［J］.Cancers(Basel),2023,15(20):5009.
[22]HASSANIH,AVAZZADEH Z,AGARWAL P,et al.A study on fractional tumor-immune interaction model related to lung cancer via generalized Laguerre polynomials［J］.BMC Medical Research Methodology,2023,23(1):189.
[23]BOCH T,KOHLERJ,JANNING M,et al.Targeting the EGF receptor family in non-small cell lung cancer-increased complexity and future perspectives［J］.Cancer Biology &Medicine,2022,19(11):1543-1564.
[24]TEDASENA,SUKRONG S,SRITULARAK B,et al.5,7,4'-Trihydroxy-6,8-diprenylisoflavone and lupalbigenin,active components of Derris scandens,induce cell death on breast cancer cell lines［J］.Biomedicine & Pharmacotherapy,2016,81:235-241.
[25]宗敏茹.非小细胞肺癌天然小分子抑制剂的筛选及其作用机理研究［D］.吉林:吉林大学,2011.
ZONG MR.Screening of natural small molecule inhibitors for non-small cell lung cancer and their mechanism of action ［D］.Jilin:Jilin University,2011.
[26]罗锐,赵月,爨向丹,等.Dehydroheliobuphthalmin与Lapatinib联合应用靶向抑制NCI-H441细胞的研究［J］.西南农业学报,2021,34(07):1425-1432.
LUO R,ZHAO Y,CUAN XD,et al.Study on the combination of Dehydroheliobuphthalmin and Lapatinib targeting the inhibition of NCI-H441 cells ［J］.Southwest Agricultural Journal,2021,34(07):1425-1432.
[27]WANG Y,LUO W,WANG Y.PARP-1 and its associated nucleases in DNA damage response ［J］.DNA Repair(Amst),2019,81:102651.
[28]GOMES AM,DA SILVA DF,BEZERRA FJ,et al.Nanohydroxyapatite-coated titanium surface increases vascular endothelial cells distinct signaling responding to high glucose concentration［J］.Journal of Functional Niomaterials,2023,14(4):188.
[29]ZHANG M,ZHANG L,HEI R,et al.CDK inhibitors in cancer therapy,an overview of recent development［J］.American Journal of Cancer Research,2021,11(5):1913-1935.